Pharsight

Cubist Pharms Llc patents expiration

1. Cubicin patents expiration

CUBICIN's oppositions filed in EPO
CUBICIN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(4 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(6 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocardi...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage

CUBICIN family patents

Family Patents

2. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(7 months ago)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jan, 2024

(a month ago)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(3 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(3 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jan, 2028

(3 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(10 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 24, 2027

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older; Treatment of microbial infections

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

3. Sivextro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(3 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(4 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: 2023-06-21

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: TABLET;ORAL

More Information on Dosage

SIVEXTRO family patents

Family Patents

4. Zerbaxa patents expiration

ZERBAXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(4 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(8 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(8 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(8 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(8 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(10 years from now)

US11278622 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(10 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(10 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(10 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(10 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(10 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(10 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2019
New Patient Population (NPP) Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN) Dec 19, 2024

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: 2023-12-20

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associate...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ZERBAXA family patents

Family Patents